Clinical trials: Hyporeflexia
Muscle Weakness
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome.
- Trial name
- 3-4DAP (NCT02090725)
- Testing
- 3-4 Diaminopyridine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jeffrey A. Cohen, MD